Inhibikase Therapeutics (NASDAQ:IKT) Upgraded to “Strong-Buy” at Lifesci Capital

Lifesci Capital upgraded shares of Inhibikase Therapeutics (NASDAQ:IKT) to a strong-buy rating in a report released on Monday morning,Zacks.com reports.

A number of other research firms have also issued reports on IKT. Weiss Ratings reaffirmed a “sell (d-)” rating on shares of Inhibikase Therapeutics in a research report on Thursday, January 22nd. Zacks Research upgraded shares of Inhibikase Therapeutics to a “hold” rating in a research note on Tuesday, December 2nd. HC Wainwright upgraded shares of Inhibikase Therapeutics to a “strong-buy” rating in a research note on Friday, December 26th. Cantor Fitzgerald raised shares of Inhibikase Therapeutics to a “strong-buy” rating in a research report on Thursday, December 11th. Finally, Wall Street Zen upgraded shares of Inhibikase Therapeutics to a “sell” rating in a research note on Saturday, December 27th. Three analysts have rated the stock with a Strong Buy rating, one has given a Hold rating and one has issued a Sell rating to the company. Based on data from MarketBeat.com, the company presently has a consensus rating of “Buy”.

Inhibikase Therapeutics Stock Performance

Shares of NASDAQ IKT opened at $2.05 on Monday. The firm has a market capitalization of $154.11 million, a PE ratio of -5.26 and a beta of 0.84. The company has a fifty day moving average of $1.73. Inhibikase Therapeutics has a 12-month low of $1.33 and a 12-month high of $2.58.

About Inhibikase Therapeutics

Inhibikase Therapeutics, Inc, a clinical stage pharmaceutical company, develops therapeutics for Parkinson’s Disease (PD) and related disorders that arise inside and outside of the brain. The company’s product candidates include IkT-148009, a small molecule Abelson tyrosine kinase inhibitor for use in the treatment of PD, as well as gastrointestinal complications that arise as early symptoms of PD, such as swallowing, dysphagia, neurogenic constipation, and multiple system atrophy; and IkT-001Pro, a prodrug of the anti-cancer agent Imatinib that is in preclinical development to minimize gastrointestinal side effects and for the treatment of blood and stomach cancers.